NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 215 filers reported holding NEVRO CORP in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $701 | -93.6% | 36,429 | -91.6% | 0.00% | -100.0% |
| Q2 2023 | $11,022 | -15.9% | 433,557 | +19.7% | 0.00% | 0.0% |
| Q1 2023 | $13,099 | +18.0% | 362,329 | +29.2% | 0.00% | 0.0% |
| Q4 2022 | $11,105 | -99.9% | 280,434 | -3.5% | 0.00% | 0.0% |
| Q3 2022 | $13,540,000 | -69.7% | 290,533 | -71.5% | 0.00% | -66.7% |
| Q2 2022 | $44,682,000 | -80.0% | 1,019,432 | -67.0% | 0.01% | -73.9% |
| Q1 2022 | $223,735,000 | +18.5% | 3,093,259 | +32.8% | 0.02% | +35.3% |
| Q4 2021 | $188,774,000 | -65.3% | 2,328,531 | -50.2% | 0.02% | -66.7% |
| Q3 2021 | $543,700,000 | -29.8% | 4,671,765 | +0.0% | 0.05% | -29.2% |
| Q2 2021 | $774,494,000 | +18.3% | 4,671,539 | -0.5% | 0.07% | +9.1% |
| Q1 2021 | $654,911,000 | -6.1% | 4,694,704 | +16.5% | 0.07% | -8.3% |
| Q4 2020 | $697,302,000 | +9.7% | 4,028,320 | -11.7% | 0.07% | -2.7% |
| Q3 2020 | $635,734,000 | +8.7% | 4,563,775 | -6.8% | 0.07% | 0.0% |
| Q2 2020 | $584,830,000 | +25.4% | 4,895,208 | +5.0% | 0.07% | 0.0% |
| Q1 2020 | $466,255,000 | +47.9% | 4,663,485 | +73.8% | 0.07% | +80.5% |
| Q4 2019 | $315,341,000 | +7.7% | 2,682,838 | -21.3% | 0.04% | 0.0% |
| Q3 2019 | $292,884,000 | +46.7% | 3,406,814 | +10.7% | 0.04% | +46.4% |
| Q2 2019 | $199,588,000 | +98.6% | 3,078,635 | +91.5% | 0.03% | +86.7% |
| Q1 2019 | $100,505,000 | +161.8% | 1,607,828 | +62.9% | 0.02% | +150.0% |
| Q4 2018 | $38,395,000 | -20.3% | 987,266 | +16.8% | 0.01% | -14.3% |
| Q3 2018 | $48,195,000 | +2940.7% | 845,526 | +4160.0% | 0.01% | – |
| Q2 2018 | $1,585,000 | +33.4% | 19,848 | +44.7% | 0.00% | – |
| Q1 2018 | $1,188,000 | -64.6% | 13,712 | -71.8% | 0.00% | -100.0% |
| Q4 2017 | $3,352,000 | +208.4% | 48,553 | +306.0% | 0.00% | – |
| Q3 2017 | $1,087,000 | +0.8% | 11,958 | -17.4% | 0.00% | – |
| Q2 2017 | $1,078,000 | +1.3% | 14,478 | +27.5% | 0.00% | – |
| Q1 2017 | $1,064,000 | -83.4% | 11,357 | -87.1% | 0.00% | -100.0% |
| Q4 2016 | $6,416,000 | -1.9% | 88,297 | +40.9% | 0.00% | 0.0% |
| Q3 2016 | $6,543,000 | -51.5% | 62,677 | -82.1% | 0.00% | -66.7% |
| Q4 2014 | $13,504,000 | – | 349,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 403,424 | $46,950,000 | 6.74% |
| HealthCor Management, L.P. | 529,230 | $61,592,000 | 2.66% |
| Sante Capital Fund, LP | 18,963 | $2,207,000 | 2.04% |
| Jackson Square Partners, LLC | 2,452,497 | $285,421,000 | 1.81% |
| Altium Capital Management LP | 51,000 | $5,935,000 | 1.56% |
| Rock Springs Capital Management LP | 635,700 | $73,983,000 | 1.56% |
| PFM Health Sciences, LP | 392,786 | $45,712,000 | 1.34% |
| Redmile Group, LLC | 542,932 | $63,186,000 | 1.10% |
| Connacht Asset Management LP | 13,555 | $1,578,000 | 1.02% |
| Integral Health Asset Management, LLC | 30,000 | $3,491,000 | 1.00% |